Alphabolin (vial)

$119.40

Substance: methenolone enanthate
Brand: Alpha Pharma
Package: 10ml ampoules (100mg/ml)

Description

Alphabolin (vial) from Alpha Pharma is a preparation with a moderate anabolic effect and weak androgenic activity. This product is Primobolan, ie methenolone enanthate in injectable form (Primobolan depot), which is an ester that has a long-term effect on cell structures.

Primobolan Effects

Primobolan has a long active period of about 2 weeks. The anabolic effect of the drug is mild, so methenolone enanthate is rarely used for weight gain. Most often, the drug is included in cycles for weight maintenance or drying.

Primobolan has no side effects associated with aromatization (gynecomastia, formation of fat deposits, swelling) and does not cause a reversal at the end of the cycle. It is safe for women, so it does not cause masculinization or fluid retention.

For some athletes, this tool is suitable for increasing muscle mass, especially if a long cycle of 10 weeks is practiced. Muscles grow slowly, but the result is more stable and qualitative. The mass collected with Primobolan is retained longer, is drier and has more relief.

Primobolan Application and Dosage

The duration of use of Primobolan is 8-12 weeks. It is necessary to perform injections of the drug not very often due to the long-term effect of the drug (one injection of 200 mg to 400 mg in 7 days). Dosage should be selected based on individual characteristics and in consultation with a specialist in the field of sports pharmacology. Taking Primobolan at a higher dosage will not increase its effectiveness, but it may increase the chance of side effects. Women are advised to stick to doses of up to 100 mg per week.The drug is contraindicated in pregnancy and lactation, and its duration when taken by women is 4-8 weeks.

Additional Information

Substance

methenolone enanthate

Package

10ml vial (100mg/ml)

Brand

Alpha Pharma

Reviews

There are no reviews yet.

Be the first to review “Alphabolin (vial)”

Your email address will not be published.